CBD Could Help Prevent and Treat Graft-Versus-Host Disease
In a patent (US Pat. No. 10,660,865) issued this week assigned to Mor Research Applications and STERO Biotechs, CBD is described as being capable of preventing and treating Graft-Versus-Host Disease (GVHD). When someone receives a tissue transplant, if the tissue contains immune cells, they may attack the host’s tissues, known as a graft-vs-host reaction.
Patent ‘865 teaches a method of preventing and treating a patient with GVHD that will undergo an allogeneic hematopoietic stem cell transplant Рa transplant from a related donor or from someone with a similar genetic makeup. A drug containing CBD, cyclosporine, and immunosuppressive drugs is administered to the patient 14 days before the transplant process and either 1 to 30 days or 7 to 180 days after the procedure.
Mor Research Applications is the Technology Transfer Office of Clalit Health Services and is based in Tel Aviv, IL and was created in partnership with STERO Biotechs, a clinical stage company focused on R&D of novel CBD therapies, also based in Israel. Explore cannabis-based pharmaceuticals and compositions using Magic Number’s Cannabis Patent Forecast®.
Related Posts
Cannabis Popularity Soars Along With Tests To Detect It
The Duquenois Levine Test is used in the field by law enforcement officers to test for THC presence in a suspected sample. The problem with…
Hound Labs, Cannabix and Vox Heat Up the Marijuana Breathalyzer Market
At the start of April 2021, Patent Forecast® released an insight going over some of the big name competitors getting their foot in the door…
Driving While High? Cannabis Sobriety Testing Heats Up
What’s the future of cannabis innovation? We see things before they happen using our Patent Forecast®. One of those is the development of…